This research report titled ‘Global Cancer Supportive Care Market 2017-2021’ provides an in-depth analysis of the market in terms of revenue and emerging market trends. This market research report also includes up to date analysis and forecasts for various market segments and all geographical regions.
The global cancer supportive care market is expected to benefit from the increasing cancer cases across the globe. The two major treatment options available for the cancer treatment are radiotherapy and chemotherapy. However, both the treatments come along with a large number of side effects, and this is expected to increase the demand for the cancer care supportive market.
This report is available at a USD 1,000 discount for a limited time only: View market snapshot before purchasing
Buy 1 Technavio report and get the second for 50% off. Buy 2 Technavio reports and get the third for free.
Technavio’s healthcare and life sciences research analysts categorize the global cancer supportive care market into the following segments by therapeutic area. They are:
- Chemotherapy-induced anemia
- Chemotherapy-induced neutropenia
- Cancer pain
Looking for more information on this market? Request a free sample report
Technavio’s sample reports are free of charge and contain multiple sections of the report including the market size and forecast, drivers, challenges, trends, and more.
The top three revenue-generating therapeutic area segments of the global cancer supportive care market are discussed below:
Anemia is a condition that develops when the blood lacks required amount of healthy red blood cells or hemoglobin. Hemoglobin is a major part of red blood cells that binds with the oxygen. Symptoms of anemia mainly include severe fatigue as the individuals suffering from the condition often do not get proper oxygen in their organs.
According to Sapna Jha, a lead oncology research analyst from Technavio, “Cancer or chemotherapeutic drugs can cause anemia in an individual. Cancer suppresses erythropoiesis, leading to anemia. Chemotherapy targets fast-dividing cancer cells as well as the healthy cells in the body. The cells in the bone marrow are highly sensitive to chemotherapy, resulting in the decreased production of red blood cells in the body.”
Neutropenia is an abnormally low concentration of neutrophils, a type of white blood cell found in the blood. Neutrophils are the major circulating white blood cells (45%-75%) that act as the primary defense for the body by destroying bacteria, bacterial fragments, and other viruses in the blood. The individuals with neutropenia are more susceptible to bacterial infections, and in the absence of prompt medical attention, the condition may become life threatening.
“Neutropenia is asymptomatic in nature. Since neutropenia weakens the defense mechanism of the body, one may acquire infections, which may cause symptoms. Fever is the most common symptom, which occurs as an immune response to various infections,” adds Sapna.
Cancer pain affects a large number of individuals undergoing cancer treatment. Not everyone suffering from cancer may go through the cancer pain; however, it is expected that around 33% of the cancer patients go through the cancer pain. The problem is highly witnessed in individuals suffering from advanced stages of the disease. Cancer itself can be a major reason for several types of pain suffered by the individual. However, cancer treatment more specifically chemotherapy may act as a potential source of cancer pain.
There are many ways to treat cancer pain, opioid analgesics and non-steroidal anti-inflammatory drugs (NSAIDs) being the most used. Pain associated with the cancer treatment has led to high consumption of these pain-relieving drugs. However, the occurrence of a large number of side effects associated with the usage of these analgesics is a challenge faced by both the healthcare providers and the individuals.
The top vendors highlighted by Technavio’s research analysts in this report are:
- Helsinn Healthcare
- Johnson &Johnson
Browse Related Reports:
- Global Hepatocellular Carcinoma Drugs Market 2017-2021
- Global Cancer Gene Therapy Market 2017-2021
- Global Castration-Resistant Prostate Cancer (CRPC) Treatment Market 2017-2021
Technavio is a leading global technology research and advisory company. Their research and analysis focuses on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions.
With over 500 specialized analysts, Technavio’s report library consists of more than 10,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio’s comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.
If you are interested in more information, please contact our media team at firstname.lastname@example.org.